← SynDRA
PF-431396
SynDRA canonical compound SYN0079279 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | PTK2 | PTK2B |
|---|
| Mechanism of action | focal adhesion kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
Cross-references
Synonyms
- RefChem:1091921
- DTXCID60420023
- PF 431396
- PF431396
- MFCD16038300
- C22H21F3N6O3S
- 3fzr
- POJZIZBONPAWIV-UHFFFAOYSA-N
- orb1305715
- SCHEMBL3144824
- SCHEMBL29381284
- CHEBI:91388
- EX-A787
- GLXC-05785
- HMS3244D04
- HMS3244D08
- HMS3244D12
- HMS3295C21
- HMS3750E11
- BDBM50246060
- s7644
- AKOS022184299
- CCG-221509
- CS-0250
- EBC-221085
- NCGC00370948-06
- AC-33053
- AS-16219
- HY-10460
- DB-074476
- PF-431396?
- PF-00431396
- BRD-K93788137-001-01-7
- N-Methyl-N-[2-[[[2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]-5-trifluoromethylpyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide
- N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide
Look up PF-431396 in the interactive SynDRA portal →